Grass pollen-induced hay fever treated with a new steroid fluocortin butylester (FCB).
The clinical effect and the side effects of a new steroid, Fluocortin butylester (FCB) in the topical treatment of hay fever was studied in a double-blind trial. The drug was administered by inhalation of a fine powder through a special inhalator (Rhinolator). The material comprised 31 patients, and the treatment period was three weeks. There was a highly significant difference in favour of FCB compared with placebo as regards the nasal symptoms blockage and discharge. Side effects were few and mild.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005448:Fluocortolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011058:Pollen; D012138:Respiratory Therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D005448:Fluocortolone; C011824:fluocortin butyl ester